(PLRX) – Press Releases
-
Pliant Therapeutics to Participate in Upcoming Investor Events
-
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
-
Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors
-
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
-
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
-
Pliant Therapeutics to Participate in Upcoming Investor Conferences
-
Pliant Therapeutics to Participate in Upcoming Investor Events
-
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected L
-
Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
-
Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis
-
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
-
Pliant Therapeutics to Participate in Upcoming Investor Conferences
-
Pliant Therapeutics Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer Highlight PLN-101095, A Novel Inhibitor of Integrins αvβ8 and αvβ1
-
Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer
-
Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023
-
Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer
-
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver
-
Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis
-
Pliant Therapeutics Appoints Minnie Kuo as Chief Development Officer
-
Pliant Therapeutics Announces Presentations at the European Respiratory Society International Congress 2023
-
Pliant Therapeutics to Participate in Upcoming Investor Conferences
-
Pliant Therapeutics Announces Three Upcoming Presentations at the European Respiratory Society International Congress 2023
-
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
-
Pliant Therapeutics Announces Initiation of BEACON-IPF, a Phase 2b Clinical Trial of Bexotegrast in Idiopathic Pulmonary Fibrosis
-
Pliant Therapeutics to Participate in Upcoming Investor Conferences
-
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™
-
Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
-
Pliant Therapeutics to Participate in Upcoming Investor Events
-
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
-
Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multi
-
Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multi
-
Pliant Therapeutics to Participate in the 22nd Annual Needham Healthcare Conference
-
Pliant Therapeutics to Participate in the 22nd Annual Needham Healthcare Conference
-
Pliant Therapeutics Announces Poster Presentations at the 2023 American Thoracic Society International Conference
-
Pliant Therapeutics Announces Poster Presentations at the 2023 American Thoracic Society International Conference
-
Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis
-
Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis
-
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results
-
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results
-
Pliant Therapeutics Announces Appointments of Darren Cline and Thomas McCourt to Board of Directors
-
Pliant Therapeutics Announces Appointments of Darren Cline and Thomas McCourt to Board of Directors
-
Pliant Therapeutics to Participate in Upcoming Investor Events
-
Pliant Therapeutics to Participate in Upcoming Investor Events
-
Pliant Therapeutics to Participate in Upcoming Investor Events
-
Pliant Therapeutics to Participate in Upcoming Investor Events
-
Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors
-
Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors
-
Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
-
Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
-
Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer
Back to PLRX Stock Lookup
